Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab in Severe or Critical COVID-19
NCT04380961Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Sirukumab with Placebo (2 arms). Primary endpoint: Time to Sustained Improvement of at Least 2 Categories on 6-point Ordinal Clinical Recovery Scale (CRS). Started Apr 2020; status: completed.
02
Drugs
sirukumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04380961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380961.